Delayed-Phase Thrombocytopenia in Patients of Coronavirus Disease 2019 (COVID-19)

Hao Zhou; Wanxin Chen; Ziping Li; Bohan Yang; Qiong Zhou; Ping Wang; Jianhua Zhu; Xuexing Chen; Peng Yang

The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.04.11.20059170 doi: medRxiv preprint virus protein-directed antibodies with platelet glycoproteins. Fourthly, virus infected megakaryocyte sheds platelets that presenting viral antigens, so anti-viral antibodies attack against platelets. Animal models with Rauscher virus infection showed viral gp70 antigen expression on platelets correlated with the development of delayed-phase thrombocytopenia [22] . On this ground, treatment using immunoregulatory agents (including intravenous immunoglobulin [IVIG] and dexamethasone) is reasonable and necessary. IVIG was administered to all these three patients thereafter and proved to be effective in 2 to 3 days. A Zika virus-infected patient suffered severe thrombocytopenia 29 days after illness onset. She was treated as presumed immune-mediated thrombocytopenia with IVIG and her platelets recovered in a few days [18] .